Krishna Institute of Medical Sciences Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 5 Aug 2026 | Healthcare Services | Market Cap: ₹33.7K Cr
Continued strong growth in revenue is expected, driven by bed expansions and adding new specialties across clusters. EBITDA margins in AP cluster expected to improve from 26% in Q2 FY25 to about 30% in 2-3 years post oncology and mother & child care additions by FY26-FY27.
From Krishna Institute of Medical Sciences Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹782
Market Cap
₹33.7K Cr
P/E Ratio
161.5
How does Krishna Institute of Medical Sciences Ltd rank in Healthcare Services?
Compare Krishna Institute of Medical Sciences Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Krishna Institute of Medical Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.1K Cr, net profit ₹33 Cr.
Full financials →📊 Revenue & Sales Performance
- →Continued strong growth in revenue is expected, driven by bed expansions and adding new specialties across clusters.
- →Telangana cluster, including Sunshine and Kondapur facilities, has significant ramp-up potential with additional beds and higher occupancy.
- →AP cluster margins expected to improve from 26% to around 30% over 2-3 years with oncology and mother & child care additions.
- →Nashik hospital expected to break even by 2Q/3Q FY26, with doctor onboarding completing by March 2025.
- →Karnataka and Kerala clusters are growth focuses, planning to scale up to 2,000 beds in Bangalore and 2,500-3,000 beds in Kerala over time.
- →International patient revenue in Telangana targeted to increase from INR 40-50 crores to INR 100-150 crores over time; Bangalore and Thane expected to contribute more.
- →ARPOB growth and inpatient/outpatient volume expansion expected to continue in Telangana and AP regions.
- →Overall, management expects to maintain EBITDA/debt below 2x and equity/debt below 1 while seizing market opportunities.
📈 Profitability & Margins
- →EBITDA margins in AP cluster expected to improve from 26% in Q2 FY25 to about 30% in 2-3 years post oncology and mother & child care additions by FY26-FY27.
- →Telangana and Andhra Pradesh clusters are expected to sustain ARPOB (Average Revenue per Occupied Bed) growth with ongoing volume and case mix improvements.
- →Nashik hospital projected to break even by Q2/Q3 FY26, with doctor onboarding to complete by March 2025, supporting revenue and occupancy ramp-up.
- →Maharashtra cluster margins expected to improve as Nashik loss narrows and Nagpur grows beyond seasonal impact.
- →Debt-to-EBITDA maintained below 2x and equity-to-debt below 1, with plans to reduce financial leverage as new hospitals mature.
- →Operating costs linked to new hospitals expected to cause some drag in FY26 but will stabilize as assets mature.
- →Management indicates confidence in maintaining steady profitability growth aligned with bed expansions and specialty additions.
🏗️ Capital Expenditure Plans
- →The company’s CAPEX guidance for FY 2026 remains around INR 500-600 crores, in line with previous estimates.
- →Ongoing capital expenditures are on track with sanctioned facilities, mainly for bed expansions and new hospitals.
- →Major projects include adding 500 beds at Kondapur (Telangana cluster) expected next financial year.
- →New hospitals are planned in Karnataka (including Sarjapur and northern Bangalore) and Kerala, aiming to scale to around 2,000 beds in Bangalore and 2,500-3,000 beds in Kerala over time.
- →Construction on new hospitals in Karnataka will start early next year with a 3-4 year commissioning timeline.
- →Kompally hospital (250 beds) in Telangana to be commissioned by year-end, operating under an O&M model requiring minimal operational cost on company books.
- →Expansion strategy focuses on bed additions in existing clusters (AP, Telangana) and new cluster growth while maintaining a debt-to-EBITDA ratio under 2 and debt-to-equity below 1.
💰 Fundraising & Capital Structure
- →The company has planned its expansions such that EBITDA to debt stays under 2x and equity to debt remains below 1 (around 0.8–0.9), indicating controlled leverage.
- →As of December 31, 2024, outstanding debt is approximately INR 1,550 crores with a projected increase to around INR 1,750 crores to fund ongoing projects.
- →Debt levels are expected to maintain a debt-equity ratio below 1 and debt-to-EBITDA below 2, with ratios likely to improve as new hospitals mature.
- →CAPEX guidance for FY '26 remains around INR 500–600 crores, and most facility sanctions have been secured; expenses are in line with budgets.
- →No explicit mention of new equity fundraise; focus appears on debt-financed expansion with management reassurance on maintaining healthy leverage and cautious borrowing.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Krishna Institute of Medical Sciences Ltd Q3 FY25 results?
Continued strong growth in revenue is expected, driven by bed expansions and adding new specialties across clusters. EBITDA margins in AP cluster expected to improve from 26% in Q2 FY25 to about 30% in 2-3 years post oncology and mother & child care additions by FY26-FY27.
What is Krishna Institute of Medical Sciences Ltd share price analysis?
Krishna Institute of Medical Sciences Ltd currently shows a neutral. The stock trades at a P/E of 161.5 with a market cap of ₹33,691 Cr. Investors should review the full earnings analysis for detailed insights.
Is Krishna Institute of Medical Sciences Ltd planning capital expenditure?
The company’s CAPEX guidance for FY 2026 remains around INR 500-600 crores, in line with previous estimates.
Keep Krishna Institute of Medical Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.